The Divergent Effects of CDPPB and Cannabidiol on Fear Extinction and Anxiety in a Predator Scent Stress Model of PTSD in Rats John Shallcross, Peter Hámor, Allison R. Bechard, Madison Romano, Lori Knackstedt and Marek Schwendt Frontiers in Behavioral Neuroscience, May 2019 | Volume 13 | Article 91 ORIGINAL RESEARCH published: 10 May 2019 doi: 10.3389/fnbeh.2019.00091 Post-traumatic stress disorder (PTSD) currently has no FDA-approved treatments that reduce symptoms in the majority of patients. The ability to extinguish fear memory associations is impaired in PTSD individuals. As such, the development of extinction-enhancing pharmacological agents to be used in combination with exposure therapies may benefit the treatment of [...]
Lire la suiteFamilial abnormalities of endocannabinoid signaling in schizophrenia Dagmar Koethe, Franziska Pahlisch, Martin Hellmich , Cathrin Rohleder , Juliane K. Mueller, Andreas Meyer-Lindenberg , E. Fuller Torrey, Daniele Piomelli and F. Markus Leweke, THE WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2018 https://doi.org/10.1080/15622975.2018.1449966 ABSTRACT Objectives : Epidemiological and experimental evidence suggests that the endocannabinoid system plays a pathophysiological role in schizophrenia. This is reflected by elevated cerebrospinal levels of the endocannabinoid anandamide in schizophrenia and its initial prodromal states. Methods : We analyzed plasma concentrations of anandamide, 2-arachidonoyl-sn-glycerol, palmitoylethanolamide and oleoylethanolamide from 25 twin pairs discordant for schizophrenia, six discordant for bipolar disorder and eight healthy twin pairs to [...]
Lire la suiteAwareness of Emotional Expressions in Cannabis Users : An Event-Related Potential Study Robert D. Torrence, Donald C. Rojas and Lucy J. Troup Frontiers in Psychology, February 2019 | Volume 10 | Article 69 ORIGINAL RESEARCH doi: 10.3389/fpsyg.2019.00069 Abstract Cannabis use has been associated with anxiogenic effects when used in low frequency for a short duration, but cannabis can also have anxiogenic effects when used heavily for a long duration. Animal studies have indicated the neurobiological mechanisms related to cannabis and anxiety; however, research has been limited on the related neurocognitive mechanisms. Previous research has indicated that cannabis use is associated with alterations in event-related potentials (ERPs). [...]
Lire la suiteCannabinoid Modulation of Functional Connectivity within Regions Processing Attentional Salience Sagnik Bhattacharyya, Irina Falkenberg, Rocio Martin-Santos, Zerrin Atakan1, Jose A Crippa, Vincent Giampietro, Mick Brammer and Philip McGuire Neuropsychopharmacology, 2015, 40, 1343–1352 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org doi:10.1038/npp.2014.258 Abstract There is now considerable evidence to support the hypothesis that psychotic symptoms are the result of abnormal salience attribution, and that the attribution of salience is largely mediated through the prefrontal cortex, the striatum, and the hippocampus. Although these areas show differential activation under the influence of delta-9-tetrahydrocannabinol (delta-9-THC) and cannabidiol (CBD), the two major derivatives of cannabis sativa, little is known about [...]
Lire la suiteThe Role of Cannabinoids in Neuroanatomic Alterations in Cannabis Users Valentina Lorenzetti, Nadia Solowij, and Murat Yücel Biological Psychiatry, 2016, 79:e17-e31 http://dx.doi.org/10.1016/j.biopsych.2015.11.013 ABSTRACT The past few decades have seen a marked change in the composition of commonly smoked cannabis. These changes primarily involve an increase of the psychoactive compound Δ9-tetrahydrocannabinol (THC) and a decrease of the potentially therapeutic compound cannabidiol (CBD). This altered composition of cannabis may be linked to persistent neuroanatomic alterations typically seen in regular cannabis users. In this review, we summarize recent findings from human structural neuroimaging investigations. We examine whether neuroanatomic alterations are 1) consistently observed in samples of regular cannabis [...]
Lire la suiteCannabis-induced altered states of consciousness are associated with specific dynamic brain connectivity states Zaytseva Y; Horáček J; Hlinka J; Fajnerová I; Androvičová R; Tintěra J; Salvi V; Balíková M; Hložek T; Španiel F; Páleníček T Journal of Psychopharmacology, 2019, 33, 7, 811-821 Research Article doi: 10.1177/0269881119849814. Abstract : Background : Cannabis, and specifically one of its active compounds delta-9-tetrahydrocannabinol in recreational doses, has a variety of effects on cognitive processes. Most studies employ resting state functional magnetic resonance imaging techniques to assess the stationary effects of cannabis and to-date one report addressed the impact of delta-9-tetrahydrocannabinol on the dynamics of whole-brain functional connectivity. Methods : Using a [...]
Lire la suiteLes cannabinoïdes dans l’Autisme : Dr Christian Sueur GRECC (Groupe de Recherches et D’Etudes Cliniques sur les Cannabinoïdes) Version actualisée juin 2019 L’autisme est une pathologie, ou plutôt un trouble majeur du développement psycho-neuro-développemental, à l’étiologie complexe et multifactorielle ; rentrent vraisemblablement en interaction, pour produire un trouble du spectre autistique, aussi bien des facteurs psychologique interactionnels précoces, qu’un terrain de fragilité ou de prédisposition génétique, à l’origine d’anomalies neurophysiologiques du développement de la connectique neuronale. Depuis près d’une vingtaine d’année, les cannabinoïdes représente progressivement une nouvelle voie d’approche thérapeutique des autismes les plus sévères. Certains parents, surtout aux USA[1], ont adopté depuis le début [...]
Lire la suiteADDICTIONS & troubles psychiatriques, REPERES Fédération Addiction, mai 2019 Avant-Propos L’association entre les pathologies addictives et psychiatriques est une source majeure de préoccupation et de difficultés pour les professionnels et les équipes des deux champs mais aussi et avant tout pour les personnes concernées et leur entourage, avec une qualité de vie fortement altérée. Ces comorbidités, ces pathologies associées ou duelles, selon les qualifications, sont en effet difficiles à repérer et à prendre en charge, chaque filière de soins, psychiatrique ou addictologique, ayant tendance à concentrer son attention et ses interventions sur la pathologie de son domaine d’expertise. Leur pronostic est péjoratif, l’évolution [...]
Lire la suiteThe Cannabis Conundrum : Thinking Outside the THC Box Sarah L. Hagerty, Sophie L. York Williams, Vijay A. Mittal, and Kent E. Hutchison The Journal of Clinical Pharmacology, 2015, 55, 8, 839–841 DOI: 10.1002/jcph.511 Keywords : cannabis, cannabinoids, D9-tetrahydrocannabinol (THC), cannabidiol (CBD), psychosis Despite nationwide movements to legalize and regulate cannabis, our understanding of its effects on human health is tenuous at best. Developing a solid evidence base regarding the health effects of cannabis is imperative given the momentum for legalization and the demand for sound regulatory practices. This present commentary will identify limitations with respect to previous research on cannabis, discuss the genesis and implications [...]
Lire la suiteTherapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain Julia De Ternay, Mickaël Naassila Mikail Nourredine, Alexandre Louvet, François Bailly, Guillaume Sescousse, Pierre Maurage, Olivier Cottencin, Patrizia Maria Carrieri and Benjamin Rolland Frontiers in Pharmacology, 2019, Volume 10, Article 627 doi : 10.3389/fphar.2019.00627 Abstract Background : Cannabidiol (CBD) is a natural component of cannabis that possesses a widespread and complex immunomodulatory, antioxidant, anxiolytic, and antiepileptic properties. Much experimental data suggest that CBD could be used for various purposes in alcohol use disorder (AUD) and alcohol-related damage on the brain and the liver. Aim : To provide a rationale for [...]
Lire la suite